Featured Archives - Stock Sector

generic-stock-raph-1280x859.jpg

Vance AuerOctober 12, 20181min27

Stocks seemingly turned around Friday morning after six days of sell-offs.  The market index was up in the early day, but is now falling back down in the afternoon. The S&P 500 (^GSPC) rose 1.59%, or 43.43 points as of 9:33 a.m. ET, setting the index on pace to snap its six-day losing streak. The Dow (^DJI) rose 1.54%, or 384.84 points, after losing a total of 1300 over the two days prior. The Nasdaq (^IXIC) advanced 2.41%, or 176.52 points.  The Dow (^DJI) was up as much as 414 points in early trading, but then erased all of those gains and briefly lost as much 52 points. The index is up just marginally. After a week of being in the red, staple stocks such as Advanced Micro Devices, Inc. (AMD), Microsoft Corporation (MSFT), Alphabet Inc. (GOOG), Apple Inc. (AAPL) are all up roughly 2% at 1:30PM today.


AVID-1280x853.jpg

Vance AuerOctober 12, 20183min14

AXT, Inc. (NASDAQ: AXTI) is up about 4.5% around 1PM today coinciding with today’s stock rally.  AXT, Inc. designs, develops, manufactures and distributes high-performance compound semiconductor substrates.  It’s customers use it’s products to fabricate integrated circuits for electronic systems that operate the latest fiber optic communications, wireless communications and lighting display applications.  The company will announce its financial results for the third quarter 2018 in a press release immediately following the close of market on October 31, 2018.  The company will also host a conference call to discuss these results on October 31, 2018 at 1:30 p.m. PT.

Allot Communications Ltd. (NASDAQ: ALLT)  provides network intelligence and security solutions to protect and personalize the digital experience worldwide. The company offers various platforms, including Allot Service Gateway 9500, Allot Service Gateway Tera, and Allot NetEnforcer for in-line deployment in traditional and virtualized network access infrastructure. Today the company’s stock is up around 3.6% mid-day partially based on released findings from it’s latest Telco Security Trends Report that examines the confidence of Internet of Things (IoT) device security by consumers living in connected homes. The report reveals that consumers have low confidence in the security of their IoT devices and are willing to pay extra for security to safeguard the connected home. The report also highlights a strong opportunity for ISPs to deliver on-target cybersecurity services to their subscribers at the network/router level.

Avid Technology, Inc. (NASDAQ: AVID) is up over 3.4% mid-day.  Avid Technology, Inc. develops, markets, sells, and supports software, hardware, and integrated solutions for video and audio content creation, management, and distribution worldwide. The company’s video products and solutions include the Media Composer product line that is used to edit film, television programming, news broadcasts, commercials, and other video content. Recently the company announced it has been named the recipient of the prestigious Philo T. Farnsworth Award by the Television Academy. The award will be presented to Avid at the 70th Emmy®Engineering Awards on October 24, 2018 in Los Angeles. The Farnsworth Award is annually given to recognize a company, organization or individual for longtime contributions that have significantly impacted television technology and engineering.

 


IDT.png

Vance AuerOctober 10, 20181min32

IDT Corporation (NYSE: IDT), through its subsidiaries, operates primarily in the telecommunications and payment industries in the United States and internationally. It operates in three segments: Telecom Platform Services, Unified Communications as a Service, and Consumer Phone Services. In pre-market trading sessions shares jumped 26% as the company reported fiscal fourth-quarter earnings. It had net income of $8.2 million, or 33 cents per share, versus a loss of $9.8 million, or a per share loss of 41 cents, for the year-ago same quarter. The company posted a revenue of $392.6 million, versus $395.0 million in the 2017 quarter. As of now the company’s stock is up 32%.


WDLF.png

Vance AuerOctober 10, 20182min30
CEO Ken Tapp

Social Life Network, Inc. (OTCQB: WDLF)  is an artificial intelligence and blockchain powered social network and e-commerce technology company based in Denver Colorado.  Since January of 2013, they have built and operated 7 international niche social networks that service the cannabis and hemp industry, residential real estate and multiple sports verticals including golf, cycling, tennis, soccer, hunting and fishing. Being integrated with other companies helps them keep their place in the market.  The company monetizes it’s networks through advertisements and digital subscriptions.  The company recently announced that it is integrating e-commerce into it’s networks and will be earning 10-30% of each sale.  With recent security concerns regarding social media sites like Facebook or Twitter, CEO Ken Tapp believes more people will flow into his company’s niche social network sites that are more focused on the user privacy.  Ken Tapp also believes his company’s stock is undervalued at around $0.15 and for today the stock is up 1%. Social Life Network plans to take MjLink.com, a subsidiary of Social Life Network that hosts it’s cannabis and hemp niche networks, public on a Canadian exchange in 2019, likely based on the fact that Canada is allowing the recreational use of marijuana starting October 17th.

 

 


CUTR.jpg

Vance AuerOctober 10, 20184min31

Cutera, Inc. (NASDAQ: CUTR) is a medical device company that designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. Today Cutera, Inc. is up over 4.4%.  The company recently announced that it expects its revenues in the third quarter of 2018 to be approximately $40 million, or mid-single digit percentage growth over the third quarter of 2017.  Based on this, the Company is revising full year 2018 revenue guidance to $165 million to $170 million, from $178 million to $181 million. Even with this news, the stock remains positive today.

 

 

Seres Therapeutics, Inc. (NASDAQ: MCRB) is up today about 1.5% around noon today. Seres Therapeutics, Inc. is a microbiome therapeutics platform company, engaging in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiple recurrent Clostridium difficile infection (CDI). The company announced it will present new data for SER-109, a microbiome candidate in development, at the IDWeek 2018 conference that was held from October 3-7 in San Francisco, CA. The findings, highlighted in two presentations, provide support for SER-109 as a potential new treatment option for individuals suffering from recurrent C. difficile infection. The company will also host a symposium on the development on novel microbiome therapeutics for C. difficile infection. “Additional SER-109 data provides valuable information about the potential mechanism of action of microbiome therapeutics, an emerging new field of medicine. Our results provide additional evidence supporting the continued development of SER-109 in patients with recurrent C. difficile infection. In addition, these new data suggest that SER-109 may have important broader public health benefits by reducing the spread of antibiotic resistance,” said Matthew Henn, Ph.D., Executive Vice President, Microbiome Research and Development at Seres Therapeutics.

Calithera Biosciences, Inc. (NASDAQ: CALA) is up over 1% today at noon. Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focusing on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.  The company recently announced two new clinical trial collaborations to evaluate Pfizer’s palbociclib, also known as IBRANCE®, and the investigational dual-mechanism poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib, each in combination with Calithera’s glutaminase inhibitor CB-839. As part of the collaboration, Pfizer will provide palbociclib and talazoparib, as well as financial support.  The ENTRATA trial, a randomized double-blind placebo-controlled study of late line patients, will enroll approximately 66 patients to receive either everolimus and CB-839 or everolimus alone. Topline results are expected in 2019.


Web Design BangladeshBangladesh Online Market